Spatial Sequencing Services

G4X TECHNOLOGY ACCESS

 

Access tomorrow’s in-situ sequencing technology today with cost-effective subcellular spatial multiomic services.

  • Targeted Transcriptomics
  • Targeted Proteomics
  • Fluorescent H&E 
Get in contact

It's time to scale your spatial multiomics

1 Flow Cell

Transcripts

Proteins

fH&E

Transcripts, Proteins, and fH&E

Image shows Transcript, Protein, fH&E readout of serial kidney tumor FFPE sections (10x10mm) from 1 of 4 flow cells in a G4X run

Start Today

Standard Projects

  • Immuno-oncology application
  • Human FFPE block starting material
  • Kidney, Breast, Lung, Colon or Bone Marrow
  • Limited to 300 RNA targets and 10 pre-selected proteins

Advanced Projects 

Get in contact

Technology Access Services Information

Please provide your information and a member of the team will be in contact to provide more information on the Technology Access Services.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Drew Spaventa

Max Reads Application Note